Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
Michael T. McCabe, Heidi M. Ott, Gopinath Ganji, et al.
Nature (2012) Vol. 492, Iss. 7427, pp. 108-112
Closed Access | Times Cited: 1684

Showing 1-25 of 1684 citing articles:

Epigenetic Regulations of GABAergic Neurotransmission: Relevance for Neurological Disorders and Epigenetic Therapy
Shikshya Shrestha, Steven M. Offer
Medical Epigenetics (2016) Vol. 4, Iss. 1, pp. 1-19
Open Access | Times Cited: 8820
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou, Jedd D. Wolchok, Lieping Chen
Science Translational Medicine (2016) Vol. 8, Iss. 328
Open Access | Times Cited: 2137
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nisha Nagarsheth, Max S. Wicha, Weiping Zou
Nature reviews. Immunology (2017) Vol. 17, Iss. 9, pp. 559-572
Open Access | Times Cited: 1841
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Katrina J. Falkenberg, Ricky W. Johnstone
Nature Reviews Drug Discovery (2014) Vol. 13, Iss. 9, pp. 673-691
Closed Access | Times Cited: 1377
Targeting EZH2 in cancer
Kimberly H. Kim, Charles W.M. Roberts
Nature Medicine (2016) Vol. 22, Iss. 2, pp. 128-134
Open Access | Times Cited: 1272
Epigenetic plasticity and the hallmarks of cancer
William Flavahan, Elizabeth Gaskell, B Bernstein
Science (2017) Vol. 357, Iss. 6348
Open Access | Times Cited: 1150
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Dongjun Peng, Ilona Kryczek, Nisha Nagarsheth, et al.
Nature (2015) Vol. 527, Iss. 7577, pp. 249-253
Open Access | Times Cited: 1026
Targeting the cancer epigenome for therapy
Peter A. Jones, Jean‐Pierre J. Issa, Stephen B. Baylin
Nature Reviews Genetics (2016) Vol. 17, Iss. 10, pp. 630-641
Closed Access | Times Cited: 1003
Writing, erasing and reading histone lysine methylations
Kwangbeom Hyun, Jongcheol Jeon, Kihyun Park, et al.
Experimental & Molecular Medicine (2017) Vol. 49, Iss. 4, pp. e324-e324
Open Access | Times Cited: 995
Tackling the cancer stem cells — what challenges do they pose?
Diwakar R. Pattabiraman, Robert A. Weinberg
Nature Reviews Drug Discovery (2014) Vol. 13, Iss. 7, pp. 497-512
Open Access | Times Cited: 948
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Yuan Cheng, He Cai, Manni Wang, et al.
Signal Transduction and Targeted Therapy (2019) Vol. 4, Iss. 1
Open Access | Times Cited: 891
EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
Wendy Béguelin, Relja Popovic, Matt Teater, et al.
Cancer Cell (2013) Vol. 23, Iss. 5, pp. 677-692
Open Access | Times Cited: 786
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
Sarah K. Knutson, Natalie M. Warholic, Tim J. Wigle, et al.
Proceedings of the National Academy of Sciences (2013) Vol. 110, Iss. 19, pp. 7922-7927
Open Access | Times Cited: 723
Phosphorylation of EZH2 Activates STAT3 Signaling via STAT3 Methylation and Promotes Tumorigenicity of Glioblastoma Stem-like Cells
Eun Hee Kim, Misuk Kim, Dong‐Hun Woo, et al.
Cancer Cell (2013) Vol. 23, Iss. 6, pp. 839-852
Open Access | Times Cited: 722
Occupying Chromatin: Polycomb Mechanisms for Getting to Genomic Targets, Stopping Transcriptional Traffic, and Staying Put
Jeffrey A. Simon, Robert E. Kingston
Molecular Cell (2013) Vol. 49, Iss. 5, pp. 808-824
Open Access | Times Cited: 688
EZH2: a novel target for cancer treatment
Ran Duan, Wenfang Du, Weijian Guo
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 679
The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression
Kui Ming Chan, Fang Dong, Haiyun Gan, et al.
Genes & Development (2013) Vol. 27, Iss. 9, pp. 985-990
Open Access | Times Cited: 659
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
Benjamin G. Bitler, Katherine M. Aird, Azat Garipov, et al.
Nature Medicine (2015) Vol. 21, Iss. 3, pp. 231-238
Open Access | Times Cited: 608
Epigenomic alterations define lethal CIMP-positive ependymomas of infancy
Stephen C. Mack, Hendrik Witt, Rosario M. Piro, et al.
Nature (2014) Vol. 506, Iss. 7489, pp. 445-450
Open Access | Times Cited: 582
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry
Alessandro Pastore, Vindi Jurinović, Robert Kridel, et al.
The Lancet Oncology (2015) Vol. 16, Iss. 9, pp. 1111-1122
Closed Access | Times Cited: 565
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
Wei Qi, Homan Chan, Lin Teng, et al.
Proceedings of the National Academy of Sciences (2012) Vol. 109, Iss. 52, pp. 21360-21365
Open Access | Times Cited: 531
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity
Laurie H. Sehn, Randy D. Gascoyne
Blood (2014) Vol. 125, Iss. 1, pp. 22-32
Closed Access | Times Cited: 506
Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
Sarah K. Knutson, Satoshi Kawano, Yukinori Minoshima, et al.
Molecular Cancer Therapeutics (2014) Vol. 13, Iss. 4, pp. 842-854
Open Access | Times Cited: 481
EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas
Faizaan Mohammad, Simon Weissmann, Benjamin Leblanc, et al.
Nature Medicine (2017) Vol. 23, Iss. 4, pp. 483-492
Closed Access | Times Cited: 468
Epigenetic balance of gene expression by Polycomb and COMPASS families
Andrea Piunti, Ali Shilatifard
Science (2016) Vol. 352, Iss. 6290
Open Access | Times Cited: 467
Page 1 - Next Page

Scroll to top